Purpose {#sec1}
=======

Eyelid tumours are relatively uncommon, representing \< 3-5% of all skin cancers in the head and neck region with an incidence of 15 cases per 100,000 individuals per year. They typically occur in the lower lid (50-66%) and inner canthus (25-30%).

Basal cell carcinoma (BCC) is the commonest histological type, representing about 85-90% of all cases, while squamous cell carcinoma (SCC) usually accounts for 2-9% of eyelid malignancies. Sebaceous gland carcinoma (SGc), Merkel cell carcinoma and malignant melanoma are rare and generally affect the upper lid \[[@cit0001],[@cit0002],[@cit0003],[@cit0004],[@cit0005]\].

A multidisciplinary team must collaborate in planning management of eyelid tumour.

The aim of treatment is definitive tumour control with functional preservation of anatomical structures. Surgery, wide excision or Mohs micrographic surgery is considered the gold standard with a high local control rate. Mohs micrographic surgery has been advocated for eyelid malignancies to ensure maximal preservation of normal tissue and to obtain margins free of disease. Orbital exenteration is necessary only in cases of locally advanced tumours with invasion of orbital structures \[[@cit0006],[@cit0007],[@cit0008],[@cit0009],[@cit0010]\].

Ophthalmic radiotherapy (RT) could be used as a curative therapy for small tumours, as adjuvant treatment after suboptimal surgical excision (with close or positive margins) or as palliative therapy for advanced and symptomatic lesions.

External beam radiotherapy (EBRT) and brachytherapy (BT) could represent a good alternative to surgery in particular when surgery may result in severe dysfunction of the lacrimal apparatus or in patients unfit because of comorbidities \[[@cit0011],[@cit0012],[@cit0013],[@cit0014],[@cit0015],[@cit0016],[@cit0017],[@cit0018],[@cit0019],[@cit0020],[@cit0021],[@cit0022]\].

Brachytherapy can be delivered by superficial (with dedicated commercial or customized applicators) \[[@cit0023],[@cit0024],[@cit0025],[@cit0026],[@cit0027],[@cit0028]\] or interstitial application (with hypodermic needles or catheters) \[[@cit0029],[@cit0030],[@cit0031],[@cit0032]\].

Compared to EBRT, the main advantages of BT include a higher localised dose around the target volume with relative sparing of critical normal tissues. BT can be administered by a radioactive source using a low-dose-rate (LDR) or a high-dose-rate (HDR) modality or by electronic BT \[[@cit0033],[@cit0034],[@cit0035]\].

The 3D optimization permits an increase of tumour coverage and a decrease of the dose to the organs at risk (OARs). The aim of this retrospective single-centre study is to evaluate long-term results and treatment-related toxicities of superficial HDR BT for eyelid carcinoma.

Material and methods {#sec2}
====================

Patient characteristics {#sec2.1}
-----------------------

The inclusion criteria were as follows: 1) patients treated with exclusive HDR-BT for primary eyelid cancer between April 2010 and August 2017; 2) multidisciplinary tumour board to confirm the treatment strategy; 3) written informed consent for the use of their anonymized data and images for research and educational purposes.

This study was part of a research project notified to our Institutional Ethical Committee (notification 726).

Patients' evaluation included complete medical history and physical examination. Careful palpation of the lesion allows evaluation of induration and attachment to periorbital structures.

An ultrasound or a CT scan was performed in case of suspected regional lymph nodes or orbital involvement. For each patient, tumour and treatment characteristics, such as histology, TNM classification \[[@cit0036]\] and BT implant characteristics, were collected. No patient had positive lymph nodes or distant metastases at diagnosis.

Treatment characteristics {#sec2.2}
-------------------------

The clinical target volume (CTV), corresponding to the visible gross tumour volume (GTV) plus a safety margin of 5-10 mm, was marked by the radiation oncologist. In all cases, an ocular tungsten shield (CIVCO Medical Solutions) was used to reduce the dose to the eye. The custom-made mould was manually built from impressions of the tumour surface for each patient using conventional thermoplastic material and standard plastic catheters embedded and/or attached on the mask surface. The number of tubes and the distance between them depended on the size of the CTV ([Figure 1](#f0001){ref-type="fig"}).

![Custom-made moulds for treatment of eyelid tumour](JCB-11-37953-g001){#f0001}

A CT scan with the applicator in situ with dummies inserted in each plastic tube and a thin metallic wire to replicate the drawn skin area (CTV) surface of the mould was performed using 2.5 mm slice thickness.

Images were sent to the planning system for 3D treatment calculation (Oncentra Masterplan Brachy Planning, Nucletron Elekta); the CTV and the surrounding organs at risk (eyeballs, lens and optic nerves) were contoured on CT slices to obtain the optimized dose distribution.

Fractionated HDR-BT was administered using a dedicated afterloader with a single radioactive source of iridium-192 (^192^Ir) (microSelectron, Nucletron Elekta).

Before the administration of each treatment fraction, the radiation therapist and the radiation oncologist placed a dedicated ocular shield under the eyelid after local anaesthesia (oxybuprocaine, eye drops) and assessed the accurate repositioning of the mould.

Evaluation {#sec2.3}
----------

Patients were reviewed after treatment to evaluate the efficacy (local control -- LC) and toxicity of the procedure every 3-6 months for the first year, every 6 months for the following four years and then annually after 5 years.

During the follow-up period, a routine annual ophthalmic examination was performed to assess any vision impairment and/or eyelid complication.

Acute and late side effects were classified according to the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) scale. Follow-up time and local control (LC) was considered from the end of BT to the date of the last evaluation. Overall survival (OS) was calculated from the start of BT to the time of death from any cause.

Results {#sec3}
=======

Between April 2010 and August 2017, 10 consecutive patients with eyelid tumours underwent superficial HDR-BT by custom-made surface mould. One patient was excluded from the analysis because of the absence of written informed consent for the use of anonymized data for research. Therefore, the final cohort of this study included 9 patients ([Table 1](#t0001){ref-type="table"}).

###### 

Characteristics of 9 patients treated with superficial high-dose-rate brachytherapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pt   Age at time of treatment (years)   Sex   Site of tumour              Histology   BT dose           Maximum acute RTOG toxicity (grade)   Maximum late RTOG toxicity (grade)   Follow-up (months)   LC
  ---- ---------------------------------- ----- --------------------------- ----------- ----------------- ------------------------------------- ------------------------------------ -------------------- ------
  1    77                                 F     Lower lid                   BCC         45 Gy in 10 fr\   1\                                    1 hyperpigmentation, epilation       90                   100%
                                                                                        (4.5 Gy/fr)       erythema, conjunctivitis                                                                        

  2    31                                 F     Lower lid                   NHL         34 Gy in 17 fr\   2\                                    1\                                   88                   100%
                                                                                        (2 Gy/fr)         erythema, oedema                      dry eye, hyperpigmentation                                

  3    70                                 F     Upper lid                   SGc         42 Gy in 12 fr\   1\                                    0                                    54                   100%
                                                                                        (3.5 Gy/fr)       erythema, oedema                                                                                

  4    41                                 M     Upper lid                   Pla         30 Gy in 12 fr\   1\                                    0                                    61                   100%
                                                                                        (2.5 Gy/fr)       erythema, conjunctivitis                                                                        

  5    66                                 M     Lower lid + inner canthus   BCC         48 Gy in 16 fr\   2\                                    1\                                   51                   100%
                                                                                        (3.6 Gy/fr)       erythema                              cutaneous retraction, epilation                           

  6    87                                 F     Lower + upper lid           SGc         42 Gy in 12 fr\   3\                                    2\                                   39                   100%
                                                                                        (3.5 Gy/fr)       erythema                              moderate corneal ulceration                               

  7    88                                 M     Lower lid                   BCC         42 Gy in 12 fr\   1\                                    1\                                   27                   100%
                                                                                        (3.5 Gy/fr)       erythema, conjunctivitis              dry eye                                                   

  8    61                                 F     Lower lid                   BCC         42 Gy in 12 fr\   1\                                    0                                    16                   100%
                                                                                        (3.5 Gy/fr)       erythema, conjunctivitis                                                                        

  9    80                                 M     Lower lid                   BCC         42 Gy in 12 fr\   1\                                    0                                    20                   100%
                                                                                        (3.5 Gy/fr)       erythema, conjunctivitis                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BCC -- basal cell carcinoma, SGc -- sebaceous carcinoma, NHL -- non-Hodgkin lymphoma, Pla -- plasmocytoma, LC -- local control

Median age was 68 years (range, 31-88 years). According to the 8^th^ TNM-UICC staging system, all lesions were stage I and less of 2 mm thick. Basal cell and sebaceous gland carcinomas were reported in 5 and 2 patients, respectively; other histological types were non-Hodgkin lymphoma and plasmacytoma.

Median delivered dose to CTV was 42 Gy (30-48 Gy) with a median dose per fraction of 3.5 Gy (2-4.5 Gy) in a median of 12 fractions (10-17) over a median of 16 days (range, 11-71 days). The lower doses were used for the patients with non-Hodgkin lymphoma and plasmacytoma ([Figure 2](#f0002){ref-type="fig"}).

![Plasmacytoma of the lower eyelid before (**A**) and 40 months after (**B**) HDR-BT. CT-based planning of HDR-BT treatment (**C**)](JCB-11-37953-g002){#f0002}

The median minimum dose covering 90% CTV (D~90~) was 96% (76-104%). Median CTV volume was 0.91 cm^3^ (0.3-3.2 cm^3^). The median and range of the maximum calculated doses (D~3cc~, dose to 0.03 cm^3^) for ipsilateral lens, ipsilateral eye and optical nerve were 35.7 Gy (18.6-40.3 Gy), 42.2 Gy (29.1-56 Gy) and 10.9 Gy (3.9-13.4 Gy), respectively. We assume that these doses were significantly lower due to the use of the dedicated ocular shield, whose presence is not taken into account by the treatment planning system.

Another aim in treatment planning was to limit the maximum dose to the skin surface to 140% of the prescribed dose \[[@cit0017]\].

In all cases but one, the treatment tolerance was excellent, without any severe procedural complications. All patients developed acute toxicity during/at the end of RT treatment. Acute toxicity reported concerned the conjunctiva and the adjacent skin (e.g. erythema and epilation): 6, 2 and 1 patients showed grade (G) 1, 2 and 3 adverse events respectively. Due to acute G2 conjunctivitis and G3 periorbital erythema, one patient temporarily interrupted treatment.

Results on late toxicity were available for all patients. Four patients did not have any late adverse event; G1 late toxicity (e.g. dry eye or skin alterations such as hyperpigmentation) was reported in 4 patients. One patient (patient no. 6; SGc of both lids; total dose 42 Gy, 3.5 Gy/fraction) developed a small corneal ulceration (G2) after one year from the end of BT. Maximum calculated doses for ipsilateral lens and eye were 35 Gy and 44 Gy, respectively and CTV volume was 0.88 cm^3^. She received only topical agents because the grade and extension of the ulcer did not warrant ocular surgery. No patients developed optic neuropathy or retinopathy, epiphora or vision impairment. After a median follow-up of 51 months (16-90 months), all patients were alive (OS 100%). No patient was lost to follow-up or had a clear evidence of local recurrence. No lymphatic or distant metastases were recorded. Cosmetic results were considered good in all cases.

Discussion {#sec4}
==========

Surgery is the standard of care for non-melanoma skin cancer, including eyelid tumours. Many factors may influence the therapeutic choice and a multidisciplinary approach is mandatory.

Since the aim of treatment is definitive tumour control with functional preservation of anatomical structures, EBRT and BT could be good alternatives to surgery in selected cases, especially for non-operable patients (medical contraindications or patient refusal) and for those patients with lesions at high risk of poor functional results after surgery.

To the best of our knowledge, there is only one randomized trial (published in 1997) comparing RT vs. surgery in patients with BCC of the face. BCC of the eyelid represents 20% of the RT group and three radiation techniques were used: interstitial BT, superficial BT and conventional EBRT. Outcome and cosmetic results were significantly better after surgery than after RT, whatever modality. No analysis of outcomes with regards to the RT technique was performed \[[@cit0037]\].

There are only a few studies available in the literature regarding the use of BT in eyelid tumour. In all of these reports, the cohorts of patients were very heterogeneous in terms of histology, treatment aims (adjuvant vs. curative BT), type of BT (LDR vs. HDR) and total dose. Acute and late toxicity are not always well discussed and data on toxicity frequencies are often lacking.

In 2015, a systematic review analysed six publications, concluding that BT has a high rate of local control (median 95.2%) with acceptable toxicity and a good functional-cosmetic outcome \[[@cit0015]\].

The most frequent acute toxicities reported were oedema and conjunctival erythema. Late toxicities reported in individual studies were unilateral cataract, entropion, conjunctivitis, eyelid malocclusion, epiphora and corneal ulcer.

In a recent meta-analysis published in 2018, the reported outcomes of skin cancers did not exhibit a significant difference between EBRT and BT in terms of local control, though the authors observed a significant benefit of BT over EBRT concerning cosmesis and functional outcome \[[@cit0020]\].

Limitations of this study include the monocentric and retrospective analysis and the low number of lesions treated, due to the infrequent presentation site of disease.

However, our data support the concept that HDR-BT for the treatment of eyelid cancer is feasible and effective with acceptable complications comparing very favourably with other published reports in the literature ([Table 2](#t0002){ref-type="table"}). In our cohort, no patients developed a local recurrence with a local control rate of 100% after a median follow-up time of 51 months. According to other publications, our treatment was well tolerated: most patients (89%) developed low-grade (G1-G2) acute toxicity concerning especially eyelid and surrounding skin and conjunctiva. Late adverse events regarded G1 skin pigmentation changes or epilation (33% of cases), but the aesthetic outcome was considered satisfactory by 100% of patients, consistent with the outcomes of other reports on HDR-BT. Acute G3 and late G2 toxicities were medically treated, without the need of surgery and without resulting in functional impairment or blindness.

###### 

Overview of relevant publications on high-dose-rate brachytherapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                    Number of patients        Site                Histology              Modality        Total dose and fractions   Median follow-up, months (range)   Local control      Good cosmetic outcome
  ---------------------------------------- ------------------------- ------------------- ---------------------- --------------- -------------------------- ---------------------------------- ------------------ -----------------------
  Martinez-Monge *et al*. \[[@cit0029]\]   1                         Lower               SCC                    Adjuvant IBT\   32 Gy/4                    6                                  100%               100%
                                                                                                                bid                                                                                              

  Azad *et al*. \[[@cit0030]\]             20                        Lower: 11\          SCC: 50%\              IBT             39 Gy/6                    39.5\                              75.6% at 5 years   100%
                                                                     Upper: 9            SGc: 40%\                                                         (18-72)                                               
                                                                                         BCC: 10%                                                                                                                

  Laskar *et al*. \[[@cit0031]\]           8                         Lower: 5\           BCC: 12.5%\            Adjuvant IBT\   21 Gy/7\                   34.5\                              100%               100%
                                                                     Upper: 3            SCC: 37.5%\            bid             35 Gy/10                   One lost to follow-up                                 
                                                                                         SGc: 50%                                                                                                                

  Mareco *et al*. \[[@cit0032]\]           17                        Lower: 15\          BCC: 94%\              IBT\            32-50 Gy/9-11              40\                                94.1%              70%
                                                                     Upper: 1\           SCC: 6%                bid                                        (7-43)                                                
                                                                     Inner canthus: 1                                                                                                                            

  Guix *et al*. \[[@cit0023]\]             16\                       --                  BCC: 100%              CBT             60-65 Gy/33-36             --                                 100%               100%
                                           Other site of face: 120                                                                                                                                               

  Franco *et al*. \[[@cit0025]\]           1                         Lower               Mantle cell lymphoma   CBT             30 Gy/20 daily             36                                 100%               --

  Montero *et al*. \[[@cit0024]\]          2                         --                  BCC: 100%              CBT             44-48 Gy/11-12             15\                                100%               --
                                                                                                                                                           (4-36)                                                

  DeSimone *et al*. \[[@cit0027]\]         1                         Bilateral eyelids   T-cell lymphoma        CBT             8 Gy/2 daily               --                                 100%               100%

  Our study                                9                         Lower: 7\           BCC: 56%\              CBT             30-48 Gy/10-17             51\                                100%               100%
                                                                     Upper: 1\           SGc: 22%\                                                         (16-90)                                               
                                                                     Both: 1             NHL: 11%\                                                                                                               
                                                                                         Pla: 11%                                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BCC -- basal cell carcinoma, SCC -- squamous cell carcinoma, SGc -- sebaceous gland carcinoma, NHL -- non-Hodgkin lymphoma, Pla -- plasmocytoma, Bid -- bis in die, 2 fractions/day, IBT -- interstitial brachytherapy, CBT -- contact brachytherapy with custom-made mould, LC -- local control

The use of advanced techniques, in particular 3D printer technology, is under investigation in order to improve the quality of treatments and the therapeutic and aesthetic outcome \[[@cit0038],[@cit0039]\].

Conclusions {#sec5}
===========

In this study, we analysed toxicity, survival and disease control in eyelid cancer patients treated with HDR-BT. Evidence from studies comparing the results of BT with other treatments is lacking in the literature. We support the concept that HDR-BT with mould applicators can deliver an effective alternative treatment technique to other RT modalities for the treatment of eyelid carcinoma. Our study shows a very good rate of disease control (LC 100%) with an acceptable toxicity profile (only one case of G3 late toxicity without sequelae).
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